The Drug Delivery and Nanotechnology (DD&N) module is a new resource available to faculty of the Wilmer Eye Institute. DD&N will take advantage of the expertise, technologies, and resources of the Wilmer Eye Institute's Center for Nanomedicine (CNM). Dr. Hanes was recruited to Wilmer in December 2009 to develop the CNM. In 2011, Dr. Hanes and his Wilmer colleagues recruited Dr. Rangaramanujam Kannan from Wayne State University, a full-professor who brought additional drug delivery nanotechnologies and expertise to the CNM. Today, the CNM occupies the 6'^ floor of Wilmer's state-of-the-art Robert H. and Clarice Smith Building, where it is an integral part of the Wilmer Eye Institute's mission. Demand by Wilmer investigators for development and characterization of drug delivery systems for small molecules, proteins, and nucleic acids have grown well beyond the available budgetary restrictions of the CNM, thus prompting the leaders of the P30 to unanimously support inclusion of the DD&N core as a new module. The funding provided will provide critical salary support for CNM personnel (25% effort of two Research Associates with complementary expertise) who will be responsible for adapting CNM drug delivery nanotechnologies to the needs of as many Wilmer faculty as possible, with priority given to those with R01 funding.

Agency
National Institute of Health (NIH)
Institute
National Eye Institute (NEI)
Type
Center Core Grants (P30)
Project #
5P30EY001765-42
Application #
9344629
Study Section
Special Emphasis Panel (ZEY1)
Project Start
Project End
Budget Start
2017-07-01
Budget End
2018-06-30
Support Year
42
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21205
Wilson, David R; Sen, Rupashree; Sunshine, Joel C et al. (2018) Biodegradable STING agonist nanoparticles for enhanced cancer immunotherapy. Nanomedicine 14:237-246
Fernandes, Kimberly A; Mitchell, Katherine L; Patel, Amit et al. (2018) Role of SARM1 and DR6 in retinal ganglion cell axonal and somal degeneration following axonal injury. Exp Eye Res 171:54-61
Date, Abhijit A; Halpert, Gilad; Babu, Taarika et al. (2018) Mucus-penetrating budesonide nanosuspension enema for local treatment of inflammatory bowel disease. Biomaterials 185:97-105
Meyer, Randall A; Mathew, Mohit P; Ben-Akiva, Elana et al. (2018) Anisotropic biodegradable lipid coated particles for spatially dynamic protein presentation. Acta Biomater 72:228-238
Goldberg, Morton F; McLeod, Scott; Tso, Mark et al. (2018) Ocular Histopathology and Immunohistochemical Analysis in the Oldest Known Individual with Autosomal Dominant Vitreoretinochoroidopathy. Ophthalmol Retina 2:360-378
Park, Tea Soon; Zimmerlin, Ludovic; Evans-Moses, Rebecca et al. (2018) Chemical Reversion of Conventional Human Pluripotent Stem Cells to a Naïve-like State with Improved Multilineage Differentiation Potency. J Vis Exp :
Hinkle, Jared T; Perepezko, Kate; Bakker, Catherine C et al. (2018) Domain-specific cognitive impairment in non-demented Parkinson's disease psychosis. Int J Geriatr Psychiatry 33:e131-e139
Duncan, Gregg A; Kim, Namho; Colon-Cortes, Yanerys et al. (2018) An Adeno-Associated Viral Vector Capable of Penetrating the Mucus Barrier to Inhaled Gene Therapy. Mol Ther Methods Clin Dev 9:296-304
Long, Da; Kanan, Yogita; Shen, Jikui et al. (2018) VEGF/VEGFR2 blockade does not cause retinal atrophy in AMD-relevant models. JCI Insight 3:
Liu, Melissa M; Cho, Chris; Jefferys, Joan L et al. (2018) Use of Optical Coherence Tomography by Nonexpert Personnel as a Screening Approach for Glaucoma. J Glaucoma 27:64-70

Showing the most recent 10 out of 851 publications